Abbott just put physiologic pacing and defibrillation on one lead. Can UltiSynq change how ICDs are implanted?
Abbott’s UltiSynq wins FDA approval and CE Mark after 98.5% implant success and 100% successful tested defibrillation in ASCEND CSP.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Abbott’s SonicForce recorded just 0.3% lesion failure, but can it challenge Shockwave in coronary calcium treatment?
Abbott has reported 97% procedural success and 0.3% target lesion failure at 30 days in its 335-patient TECTONIC study of SonicForce. The findings support the investigational system's regulatory development, although the single-arm trial does not establish superiority over existing coronary lithotripsy devices.
Medical Devices & Diagnostics
Can Teleflex’s Freesolve scaffold challenge permanent drug-eluting stents?
Teleflex completes BIOMAG-LL enrollment in 102 patients, testing longer Freesolve magnesium scaffolds ahead of European regulatory expansion.
Medical Devices & Diagnostics
Could a sensor 10 times shorter challenge Dexcom and Abbott? Ascensia is betting on Sava
Ascensia backs Sava's $36M glucose microsensor push, but clinical validation and CE marking remain critical before its planned European launch.
Medical Devices & Diagnostics
Abbott’s CardioMEMS app approval brings heart pressure data directly to patients
Abbott Laboratories (NYSE: ABT) has received United States Food and Drug Administration approval for new patient-facing capabilities within its CardioMEMS HF System, allowing care teams to give patients access to pulmonary artery pressure trends through the CardioGuide HF App. The update also introduces a Dynamic Treatment Plan feature through which clinicians can communicate personalised medication
Features & Analysis
FDA approved Abbott’s dual-energy AFib catheter. Can procedural flexibility beat single-energy simplicity?
Abbott Laboratories has received FDA approval for TactiFlex Duo, a focal ablation catheter capable of delivering both pulsed-field and radiofrequency energy. The system enters a rapidly expanding pulsed-field ablation market with a different proposition: instead of replacing thermal ablation entirely, it lets electrophysiologists choose between energy types during the same procedure.
Medical Devices & Diagnostics
Abbott wins FDA approval for dual-energy TactiFlex Duo. Does AFib ablation need two tools in one?
Abbott’s TactiFlex Duo combines pulsed field ablation and radiofrequency energy in one contact-force catheter, giving electrophysiologists a way to move between tissue-selective PFA and conventional thermal ablation without changing platforms during an AFib procedure.
Medical Devices & Diagnostics
Abbott Libre Duo watches a diabetes danger signal CGMs have historically missed
Abbott Laboratories has secured FDA De Novo authorization for Libre Duo 10 Day, the first wearable in the United States to continuously monitor ketones and the first device globally to continuously measure glucose and ketones together.
Medical Devices & Diagnostics
HealthTab brings Abbott HbA1c and lipid testing into UK pharmacies under multi-year deal
Avricore Health’s HealthTab will distribute Abbott’s Afinion 2 through NHS-linked pharmacies, combining rapid HbA1c and lipid testing with a connected platform for community-based screening.
Pharma & Biotech
FDA approves Freenome SimpleScreen CRC blood test as Abbott prepares US launch
FDA approves Freenome’s SimpleScreen CRC blood test as Abbott plans a fall launch. See its benefits, limits and colonoscopy requirement.